Monte Rosa Therapeutics Inc Working Capital to Net Assets Ratio
Monte Rosa Therapeutics Inc working capital to net assets ratio. Monte Rosa Therapeutics Inc (GLUE) has a Working Capital to Net Assets ratio of 117.4% as of June 2026. Working capital of $569.52 Million (current assets of $636.33 Million minus current liabilities of $66.81 Million) is measured against net assets of $485.05 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. Check Monte Rosa Therapeutics Inc (GLUE) tangible net worth to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Monte Rosa Therapeutics Inc (2019–2025)
Working capital to net assets ratio of Monte Rosa Therapeutics Inc from 2019 to 2025. This chart shows how Monte Rosa Therapeutics Inc's Working Capital to Net Assets ratio has evolved across 7 annual periods from 2019 to 2025. As of June 2026, the ratio stands at 117.4%, reflecting working capital of $569.52 Million against net assets of $485.05 Million USD. See GLUE cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Monte Rosa Therapeutics Inc Working Capital to Net Assets Ratio by Year (2019–2025)
Monte Rosa Therapeutics Inc working capital to net assets ratio by year from 2019 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for Monte Rosa Therapeutics Inc from 2019 to 2025, covering 7 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see GLUE total assets.
| Year | WC/NA Ratio | Working Capital (USD) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 141.2% | $328.97 Million | $233.06 Million | $393.19 Million | $64.21 Million | ▲ +42.3 pp |
| 2024 | 98.9% | $220.49 Million | $222.94 Million | $377.44 Million | $156.95 Million | ▼ -6.9 pp |
| 2023 | 105.8% | $189.62 Million | $179.25 Million | $236.21 Million | $46.59 Million | ▲ +13.6 pp |
| 2022 | 92.2% | $250.32 Million | $271.41 Million | $275.89 Million | $25.57 Million | ▼ -3.3 pp |
| 2021 | 95.5% | $332.03 Million | $347.51 Million | $348.67 Million | $16.64 Million | ▲ +124.9 pp |
| 2020 | -29.4% | $14.32 Million | $-48.73 Million | $43.59 Million | $29.27 Million | ▲ +15.6 pp |
| 2019 | -45.0% | $5.47 Million | $-12.15 Million | $9.76 Million | $4.29 Million | — |